Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Amgen Adds $1B to Manufacturing Expansion | Contract Pharma

What are you searching for?

Sign in
Breaking News

Amgen Adds $1B to Manufacturing Expansion

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen expects to invest $1 billion during the next four years to expand its manufacturing capacity in Puerto Rico to meet rising global demand for the company’s products. The investment will include expansion of existing facilities in the company’s manufacturing complex in Juncos, PR, and the construction of a new formulation, fill and finish facility. Amgen expects to add approximately 500 staff members in PR by 2010.

In PR, the company expects to expand its Neupogen and Neulasta bulk protein manufacturing facility as well as the newly built Epogen and Aranesp bulk plant. In addition, Amgen plans to construct a new formulation, fill and finish facility along with upgrades to its existing formulation, fill and finish operations.

Amgen previously announced plans to invest approximately $1 billion in new bulk protein manufacturing and formulation, fill and finish facilities in Cork, Ireland, to give the company capacity closer to the patients it serves in Europe. Amgen also plans to expand its existing R&D operations in Cambridge, MA, South San Francisco, Seattle, and Cambridge, U.K., and build a new development center in Uxbridge, U.K.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters